Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis

Cynthia Buness, Keith Lindor, Tamir Miloh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.

Original languageEnglish (US)
Pages (from-to)210-213
Number of pages4
JournalPediatric Gastroenterology, Hepatology and Nutrition
Volume19
Issue number3
DOIs
StatePublished - 2016

Fingerprint

Sclerosing Cholangitis
Vancomycin
Ulcerative Colitis
Bile Ducts
Anti-Bacterial Agents
Cholestasis
Immunologic Factors
Liver Diseases
Fibrosis
Therapeutics
Drug Therapy
Liver
Enzymes

Keywords

  • Liver diseases
  • Primary sclerosing cholangitis
  • Ulcerative colitis
  • Vancomycin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hepatology
  • Gastroenterology

Cite this

Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis. / Buness, Cynthia; Lindor, Keith; Miloh, Tamir.

In: Pediatric Gastroenterology, Hepatology and Nutrition, Vol. 19, No. 3, 2016, p. 210-213.

Research output: Contribution to journalArticle

@article{645dcfd989314d549f39029bca7a3d7c,
title = "Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis",
abstract = "Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.",
keywords = "Liver diseases, Primary sclerosing cholangitis, Ulcerative colitis, Vancomycin",
author = "Cynthia Buness and Keith Lindor and Tamir Miloh",
year = "2016",
doi = "10.5223/pghn.2016.19.3.210",
language = "English (US)",
volume = "19",
pages = "210--213",
journal = "Pediatric Gastroenterology, Hepatology and Nutrition",
issn = "2234-8646",
publisher = "Korean Society of Pediartic Gastroenterology, Hepatology and Nutrition",
number = "3",

}

TY - JOUR

T1 - Oral vancomycin therapy in a child with primary sclerosing cholangitis and severe ulcerative colitis

AU - Buness, Cynthia

AU - Lindor, Keith

AU - Miloh, Tamir

PY - 2016

Y1 - 2016

N2 - Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.

AB - Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.

KW - Liver diseases

KW - Primary sclerosing cholangitis

KW - Ulcerative colitis

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84992690630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992690630&partnerID=8YFLogxK

U2 - 10.5223/pghn.2016.19.3.210

DO - 10.5223/pghn.2016.19.3.210

M3 - Article

VL - 19

SP - 210

EP - 213

JO - Pediatric Gastroenterology, Hepatology and Nutrition

JF - Pediatric Gastroenterology, Hepatology and Nutrition

SN - 2234-8646

IS - 3

ER -